ECD Proteins
SKU: PME-C100042 Target: FAP
Price: 10μg $118.00; 50μg $409.00 ; 100 μg $615.00
ECD Proteins
SKU: PME-C100030 Target: CD7
Price:10μg $120.00; 50μg $380.00; 100μg $570.00
ECD Proteins
SKU: PME-C100003 Target: IL9
Price:10μg $120.00; 50μg $380.00; 100μg $570.00
ECD Proteins
SKU: PME-C100080 Target: MET
Price: 10μg $79.00 ; 50μg $281.00 ; 100μg $422.00
ECD Proteins
SKU: PME-C100032 Target: CA9
Price:10μg $95.00; 50μg $330.00; 100μg $500.00
ECD Proteins
SKU: PME-C100020 Target: 5T4
Price:10μg $120.00; 50μg $380.00; 100μg $570.00
ECD Proteins
SKU: PME-C100009 Target: MDK
Price: 10μg $120.00 ; 50μg $409.00 ; 100 μg $615.00
ECD Proteins
SKU: PME-C100025 Target: AXL
Price:10μg $120.00; 50μg $380.00; 100μg $570.00
ECD Proteins
SKU: PME-C100084 Target: SEZ6
Price: 10μg $79.00 ; 50μg $281.00 ; 100μg $422.00
ECD Proteins
SKU: PME-C100035 Target: PSMA
Price:10μg $120.00; 50μg $380.00; 100μg $570.00
ECD Proteins
SKU: PME-C100036 Target: EGFR
Price:10μg $120.00; 50μg $380.00; 100μg $570.00
ECD Proteins
SKU: PME-C100037 Target: CD3E
Price:10μg $120.00; 50μg $380.00; 100μg $570.00
ECD Proteins
SKU: PME-C100052 Target: CD30
Price:10μg $129.00; 50μg $476.00; 100μg $714.00
ECD Proteins
SKU: PME-C100027 Target: MICA
Price: 10μg $118.00; 50μg $429.00 ; 100 μg $645.00
ECD Proteins
SKU: PME-C100034 Target: MICB
Price: 10μg $118.00; 50μg $429.00 ; 100 μg $645.00
ECD Proteins
SKU: PME-C100044 Target: CDH6
Price: 10μg $118.00; 50μg $429.00 ; 100 μg $645.00
ECD Proteins
SKU: PME-C100043 Target: CD73
Price: 10μg $118.00; 50μg $429.00 ; 100 μg $645.00
ECD Proteins
SKU: PME-C100048 Target: CD47
Price: 10μg $118.00; 50μg $409.00 ; 100 μg $615.00
ECD Proteins
SKU: PME-C100051 Target: HER3
Price: 10μg $100.00; 50μg $358.00 ; 100 μg $528.00
ECD Proteins
SKU: PME-C100053 Target: CD3D
Price: 10μg $100.00; 50μg $358.00 ; 100 μg $528.00
Posts found
CD73: A Potential Target in Cancer Immunotherapy
On September 25, 2024, I-Mab announced a strategic collaboration with Sanofi to develop, produce, and [...]
Oct
HER3/ERBB3: Dominating Cancer Therapy with ADCs and Beyond
On September 17, a collaboration between Daiichi Sankyo and Merck announced that patritumab deruxtecan, a [...]
Sep
Research Progress on BCMA-Targeted Therapies in Multiple Myeloma
On August 27, 2024, Legend Biotech’s BCMA CAR-T product, Carvykti® (generic name: ciltacabtagene autoleucel injection), [...]
Sep
Research Progress on Targeting BCMA in Autoimmune Diseases
The B cell maturation antigen (BCMA), a target that gained prominence due to its association [...]
Aug
The Fate of ADAM9 ADCs: What Lies Ahead After AbbVie’s Decision?
In March 2024, AbbVie announced its decision to terminate the development of IMGC936 in collaboration [...]
Aug
CDH6 ADC: Promising Results for Ovarian Cancer Treatment!
In March 2024, a preclinical study titled “Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a [...]
Jul
Nectin-4: A Promising Target in Antibody-Drug Conjugate (ADC) Therapy
During the 2024 ASCO conference, Professor Zhang Jian of Fudan University’s Cancer Hospital unveiled the [...]
Jun
FRα/FOLR1 – Another Anti-cancer Target Fueled by the ADC
Folate receptor alpha (FRα), due to its differential expression in various tumor or cancer tissues [...]
May
Immune Checkpoint B7-H3: Exploring the Current Landscape of Targeted Therapies
In December 2023, GlaxoSmithKline (“GSK”) invested $1.71 billion to obtain the global exclusive rights for [...]
May
CDH17: A Target for Diverse Solid Tumor Therapies—Will It Lead to Significant Breakthroughs in Cancer Treatment?
In March 2022, a study published in Nature Cancer highlighted Cadherin 17 (CDH17) as an [...]
Apr